Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
На конгрессе ESMO представили результаты российского исследования препарата трифлуридин/типирацил у пациентов с рефрактерным метастатическим колоректальным раком
На конгрессе ESMO представили результаты российского исследования препарата трифлуридин/типирацил у пациентов с рефрактерным метастатическим колоректальным раком
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. World Health Organisation. Globocan (2012), colorectal cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=colorectal
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
________________________________________________
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.